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Abstract
Background: Metabolic alterations relevant to postprandial dyslipidemia were previously identified in the intestine
of obese insulin-resistant subjects. The aim of the study was to identify the genes deregulated by systemic insulin
resistance in the intestine of severely obese subjects.
Methods: Transcripts from duodenal samples of insulin-sensitive (HOMA-IR < 3, n = 9) and insulin-resistant
(HOMA-IR > 7, n = 9) obese subjects were assayed by microarray (Illumina HumanHT-12).
Results: A total of 195 annotated genes were identified as differentially expressed between these two groups
(Fold change > 1.2). Of these genes, 36 were found to be directly involved in known intestinal functions, including
digestion, extracellular matrix, endocrine system, immunity and cholesterol metabolism. Interestingly, all differentially
expressed genes (n = 8) implicated in inflammation and oxidative stress were found to be upregulated in the intestine
of insulin-resistant compared to insulin-sensitive subjects. Metabolic pathway analysis revealed that several signaling
pathways involved in immunity and inflammation were significantly enriched in differently expressed genes and were
predicted to be activated in the intestine of insulin-resistant subjects. Using stringent criteria (Fold change > 1.5;
FDR < 0.05), three genes were found to be significantly and differently expressed in the intestine of insulin-
resistant compared to insulin-sensitive subjects: the transcripts of the insulinotropic glucose-dependant
peptide (GIP) and of the β-microseminoprotein (MSMB) were significantly reduced, but that of the humanin
like-1 (MTRNR2L1) was significantly increased.
Conclusion: These results underline that systemic insulin resistance is associated with remodeling of key
intestinal functions. Moreover, these data indicate that small intestine metabolic dysfunction is accompanied with a
local amplification of low-grade inflammatory process implicating several pathways. Genes identified in this study are
potentially triggered throughout the development of intestinal metabolic abnormalities, which could contribute to
dyslipidemia, a component of metabolic syndrome and diabetes.
Background
Insulin resistance and type 2 diabetes (T2D) are fre-
quently associated with fasting and postprandial dyslip-
idemia. Exaggerated hepatic VLDL production and
reduced hepatic triglyceride-rich lipoprotein (TRL)
clearance have long been suggested as the main mecha-
nisms involved in this complication. However, growing
evidence suggests that postprandial and fasting plasma
lipids are regulated by an interaction between hepatic
and intestinal metabolism [1]. In particular, the gut epi-
thelium is well equipped to efficiently transform and
transport alimentary lipids by employing competent
lipoprotein assembly in synchronization with the whole-
body homeostasis [2]. Postprandial overproduction of
triglyceride-rich lipoproteins (TRL), mostly chylomi-
crons (CMs), have been associated to postprandial dys-
lipidemia in several well-designed human studies [1].
Clearly, development of insulin resistance and T2D has
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been linked to alterations in key intestinal metabolic
functions [3–5].
Various animal models have been employed to examine
the impact of systemic insulin resistance on intestinal lipid
metabolism [3–9]. Most of the studies evidently report the
role of local insulin resistance in promoting lipid metabol-
ism dysregulation. However, only limited investigations
have been performed in humans. Recently, our group [10]
along with other laboratories [11, 12] have tested this hy-
pothesis in insulin-resistant and hyperlipidemic subjects.
As observed in other metabolic organs (i.e., liver, adipose
tissue and muscle), the small intestine of insulin-resistant
subjects displayed evidence of insulin signaling defects
[10]. As stressed by our findings, local insulin resistance
was likely the result of an exacerbated pro-oxidative and
pro-inflammatory local environment, which resulted in
enhanced de novo lipogenesis rate and apolipoprotein
(apo) B48 biogenesis along with exaggerated TRL produc-
tion and secretion [10]. Presence of oxidative stress in the
intestine of insulin-resistant subjects was evidenced by in-
creased malondialdehyde and conjugated dienes levels
and by a decreased superoxide dismutase (SOD) antioxi-
dant activity [10]. Conversely, the low grade inflammatory
state was highlighted by enhanced p38 MAPK and NF-κB
pathway activation and by increased expression levels of
TNF-α, IL-6, ICAM and PTGS-2 in the intestine of
insulin-resistant subjects [10]. Adverse changes in the ex-
pression of key proteins involved in lipid/lipoprotein me-
tabolism [i.e., liver and intestinal specific fatty acid binding
proteins (FABP), microsomal triglyceride transfer protein
(MTP)] and cholesterol metabolism [i.e., adenosine
triphosphatase-binding cassette A1 (ABCA1) and propro-
tein convertase subtilisin/kexin type 9 (PCSK9)] were also
observed in insulin-resistant subjects [10].
Although dysfunctional intestinal lipid metabolism
and concomitant postprandial TRL overproduction
seem to pave the way to the development of athero-
genic dyslipidemia and increased risks of cardiovascular
diseases [13], the intra-enterocyte signalling pathways
and intrinsic mechanisms, likely orchestrated by add-
itional critical proteins, have remained obscure. There-
fore, our objective in the present study was to delineate
potential mechanisms and unravel new gene candidates
using whole-genome gene expression microarray, one
of the most powerful tools that allows the measurement
of all known genes simultaneously and has been used
extensively in biomedical researches. Our experimental
approach has directly focused on human intestine to
avoid limitations inherent to animal models. Taking
advantage of the unique opportunity to obtain small
intestine samples following bariatric surgery, we es-
tablished tissue-specific gene expression signatures that
characterized insulin-resistant and insulin-sensitive
obese subjects.
Methods
Subjects and tissue sampling
Twenty severely obese subjects (BMI ≥ 40 kg/m2), with-
out T2D according to their medical files and undergoing
biliopancreatic diversion, were recruited at the Quebec
Heart and Lung Institute, Laval University (Quebec City,
Canada). Insulin and glucose levels were assessed in the
plasma of each subject to calculate the homeostatic model
assessment of insulin resistance (HOMA-IR) index. These
subjects (10 women and 10 men) were assigned into two
groups matched for sex, age (±10 years) and body mass
index (BMI) (±5 units), but with either relatively low (<3)
or high (>7) HOMA-IR. None of these subjects received a
therapy with hypoglycaemic agents, cholesterol- or TG-
lowering agents. Duodenum specimens were obtained
during the surgery. The small intestine samples were im-
mediately washed and frozen in liquid nitrogen and stored
at −80 °C for subsequent RNA extraction. Written in-
formed consent was obtained from all subjects. The pro-
ject was approved by the ethics committees of Quebec
Heart and Lung Institute (Quebec City, Canada) and
Sainte-Justine Research Center (Montreal, Canada).
Anthropometry, lipid profile and glucose homeostasis
BMI and overnight fasting blood samples were obtained
in the morning before the surgery. Total cholesterol,
free cholesterol and triglyceride levels were estimated
in the plasma by colorimetric enzymatic kits (Roche
Diagnostic, Indianapolis, USA). Glucose was assessed
using the glucose oxidase method and insulin was
quantified with the ultrasensitive insulin assay on the
Access® immunoassay system (Beckman Coulter, Brea,
USA). The HOMA-IR index was calculated using the
following formula: fasting insulin (μU/mL) × fasting
glucose (mmol/L)/22.5 [14].
Intestinal Caco-2/15 cell culture
For functional studies, we used the intestinal Caco-2/15
cells [15], generated from a clone of the original Caco-2
(ATCC, Rockville, USA), were cultured at sub-confluence
in MEM supplemented with 5 % fetal bovine serum, 1 %
non-essential amino acids and 1 % Penicillin/Streptomycin
(Gibco, Grand Island, USA) as previously described [15].
For individual experiments, cells were plated at a density of
5 × 105 cells/well in flat-bottom 6-well plates (Costar, Cam-
bridge, MA). Cells were cultured for 12–15 days post-
confluence, which represents an appropriate period to
reach full differentiation and study lipid and lipoprotein
metabolism as well as oxidative stress and inflammation
[16]. Cells were serum starved for 18 h and then incubated
in presence or absence of iron-ascorbate (Fe/Asc) (200 μM/
2 mM) for 6 h or LPS (150 μg/mL) for 24 h at 37 °C.
Veilleux et al. BMC Gastroenterology  (2015) 15:119 Page 2 of 12
Messenger RNA preparation
Total RNA was isolated from intestinal tissue using the
RNeasy lipid tissue extraction kit and on-column DNase
treatment following the manufacturer’s recommenda-
tions (Qiagen, Valencia, USA). RNA concentration and
quality were respectively assessed using the NanoDrop
spectrophotometer (Thermo Scientific, Wilmington,
USA) and the Agilent Technologies 2100 bioanalyzer
(Agilent, Santa Clara, USA). Only total RNA samples
with a RNA integrity number higher than seven were in-
cluded in the following experiments.
Gene expression profile analysis
Microarray experiments were performed at the McGill Uni-
versity and Génome Québec Innovation Centre (Montréal,
Canada). Gene expression profile was assessed using the
Illumina HumanHT-12 v4 BeadChip (Illumina, San Diego,
USA) technology. Briefly, reverse transcription of 250 ng
total RNA and complementary RNA synthesis and biotin
labeling were performed using the TargetAmp Labeling Kit
(Illumina, San Diego, USA). Hybridization of 700 ng of
each biotinylated cRNA sample on the BeadChip was per-
formed at 58 °C for 16–18 h. BeadChips were scanned
using the Illumina Bead Array Reader (Illumina, San Diego,
USA). Main observations of the microarray experiments
were validated by quantitative real-time PCR (qPCR).
Complimentary DNA was generated using the superscript
first strand synthesis system (Invitrogen, Carlsbad, USA).
Real-time cDNA amplification was performed in triplicate
using SYBR Green with the 7500 Real-Time PCR System
(Applied Biosystems, Foster City, USA) for 40 cycles. Target
gene amplifications were normalized to ATP synthase 5
subunit O (ATP5O) expression levels. The relative mRNA
fold changes (insulin-resistant compared to insulin-
sensitive subjects) were calculated using the 2−ΔΔCt
method. Validation was performed to ensure optimal
cDNA amplification efficiency of the target and reference
genes. Primer sequences used for PCR were as follows
(sense; anti-sense): GIP (TGGCAGTGGGACTAGGAGA
G; GTTGAGGGCTGCTCACCTTA), MSMB (GCTTT
GCCTGGATGTACCTG; CCTGGTTGAATCTCCTGGA
A), MTRNR2L1 (CACTTGTTCCTTAAATAGGGACTT




Differences in metabolic parameters between insulin-
sensitive and insulin-resistant were tested using paired Stu-
dent’s t-test and repeated measures analysis of variances
(ANOVA). Microarray expression data were extracted
using the Robust Multichip Average (RMA) method [17]
and were analyzed using R. Prior to microarray analysis,
one pair of male subjects was removed as one sample failed
the quality control and was considered as an outlier using
the distance distribution clustering analysis. Differentially
expressed genes were identified as having an estimated
fold-change of at least 1.5 (intestine of insulin-resistant
subjects compared to that of insulin-sensitive subjects) and
a false discovery rate (FDR) smaller than 0.05 was calcu-
lated using the Significant Analysis of Microarrays method
[18]. In addition to this stringent primary analysis, a second
set of differentially expressed genes were identified using
more permissive analysis parameters to perform pathway
analysis [19, 20]. A total of 195 genes with a fold change
greater than 1.2 and with a p value smaller than 0.05 were
included in the metabolic pathway analysis [Ingenuity
Pathway Analysis (IPA) software, Qiagen, Redwood City,
USA]. Gene Ontology (GO) enrichment analysis, including
p-values for all genes present on the array, was carried out
using GOrilla (http://cbl-gorilla.cs.technion.ac.il/). Briefly,
the 47 313 probes were ranked according to their absolute
fold change and mapped to the 36 683 corresponding
genes in the GOrilla system. After extraction of the highest
ranking instance of duplicates, 21 918 genes were used for
testing. A total of 17 978 of these genes were associated
with a gene ontology biological process terms. GO terms
with enrichment p-value lower than 10−5 were considered.
Messenger RNA expression levels (ΔΔCt) measured by
qPCR were compared using the Wilcoxson signed-rank
test or the Student’s t-test, respectively, for experiments
including human samples and Caco-2/15 cells. Spearman
correlation coefficients were computed to quantify the as-
sociation between specific microarray data and qPCR
expression values. Differences were considered to be sta-
tistically significant at p < 0.05. Statistical analyses were
performed with SAS software (SAS Institute, Cary, USA).
Results
Messenger RNA expression was measured in the intestine
of 18 severely obese women (n = 10) and men (n = 8). All
subjects were candidates for bariatric surgery, and speci-
mens of the proximal small intestine were obtained during
the procedure. Subjects were 42.6 years on average and
had a mean BMI of 53.8 kg/m2 [10]. The study sample
was selected from a larger pool to establish two groups
paired for sex, age and BMI but with divergent HOMA-IR
index values, namely the insulin-sensitive (HOMA-IR < 3,
n = 9) and the insulin-resistant (HOMA-IR > 7, n = 9) obese
subjects [10]. No differences in age (45.0 ± 10.0 vs. 40.3 ±
10.1 years) and BMI (54.0 ± 7.3 vs. 53.7 ± 7.6 kg/m2) were
observed between the two groups (Fig. 1a, b). Nonetheless,
insulin-resistant subjects were characterized by a higher
HOMA-IR index and elevated glycosylated hemoglobin,
which is in line with the study design (Fig. 1c, d). They
also present a less favorable fasting plasma lipid profile
characterized by higher triglyceride (TG) and lower HDL-
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cholesterol concentrations, as well as smaller LDL parti-
cles (Fig.1 e–h).
Microarray analysis of duodenal samples from insulin-
sensitive (n = 9) and insulin-resistant (n = 9) obese subjects
reveals a relatively low intergroup variability in gene expres-
sion profiles. A total of 195 annotated genes were identified
in the intestine of these subjects using relatively permissive
analysis parameters (fold change > 1.2 and p value < 0.05)
[19, 20]. The complete list of differentially expressed genes
are included in the [see Additional file 1 : Table S1]. Of
these differentially expressed genes, 36 were known to be
involved in different small intestine functions such as sig-
naling peptides, inflammation, oxidative stress, nutrient
transport, extracellular matrix, digestive functions, immun-
ity and cholesterol homeostasis (Table 1). These results
pointed out the presence of alterations in several key intes-
tinal functions in presence of systemic insulin resistance.
Some interesting trends were noted. Expression levels of
several genes relevant to intestinal extracellular matrix, in-
cluding those coding for mucin proteins as well as for me-
talloproteinase 7 and villin 1, were altered in presence of
insulin resistance (Table 1). Expression levels of enzymes
involved in a number of digestive steps (Pepsinogen A, lac-
tase, β-galactosidase, pancreatic lipase, trypsin 1 and elas-
tase) were also modified and may collectively denote
changes in the interaction between the gut and the alimen-
tary and metabolic status. It is also noteworthy that all dif-
ferentially expressed genes involved in inflammation and
oxidative stress pathways (PTGS2, DUSD1, S100A8,
S100A9, IL1B, GPX8, FOS and JUN) were found to
be upregulated in insulin-resistant subjects. Finally, we
have found that several major histocompatibility complex
members were differentially expressed in the intestine of
insulin-sensitive and insulin-resistant obese subjects.
Subsequently, the 195 differentially expressed genes in
the intestine were investigated using the Ingenuity Path-
way Analysis (IPA) software. This approach allowed
the identification of 17 metabolic pathways significantly
enriched in differentially expressed genes (Table 2). Fifteen
of these pathways are predicted to be activated in the in-
testine of insulin-resistant subjects, and almost half of
them are known to participate in inflammatory cell signal-
ing pathways (JNK, TREM1, IL1α, IFNγ, SELPLG, P38
MAPK and TLR4). Interestingly, the IPA analysis predicts
the activation of the p38 MAPK pathways, which is coher-
ent with our previous study [10]. Indeed, we have demon-
strated that p38 MAPK activating phosphorylation is
increased in the intestine of insulin-resistant subjects com-
pared to the intestine of insulin-sensitive subjects [10].
Other pathways found to be upregulated were involved in
mitosis (PDGF, ERK and MAP2K1/2), transcription (C/
EBPα, NUPR1, SMAD4), immunity (CD40LG) and coagu-
lation (F7). Concerning the two pathways that are predicted
to be down-regulated in the intestine of insulin-resistant
subjects, we noticed that immunity (immunoglobulin G,
IgG) and gene expression regulation (histone deacetylases,
HDAC) seem to be disturbed in presence of insulin
resistance. Results of this analysis reveal several changes
Fig. 1 Anthropometric, glucose homeostasis and lipid profile
parameters in insulin-sensitive (n = 9) and insulin-resistant subjects
(n = 9). Overnight fast values of a age, b BMI, c HOMA-IR index, d
glycosylated hemoglobin (%), e) plasma TG (mmol/L), f HDL cholesterol
(mmol/L), g LDL cholesterol (mmol/L), and h LDL particle size are shown.
Values are mean ± SEM
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in the activation of key metabolic pathway and clearly sug-
gest that insulin resistance is involved in the development
of a chronic low grade pro-inflammatory intestinal
microenvironment.
The most significant Gene Ontology (GO) terms identi-
fied by GO enrichment analysis, listed in the [see
Additional file 1: Table S2], strongly support the results
obtained with IPA. Indeed, several GO terms are related
to: (i) immunity (GO: 0002682, 0006955, 0002376,
0050776, 0002684); (ii) digestion process (GO:0007586,
0008152, 0044248, 0002684); and (iii) response to oxida-
tive stress and inflammation (GO:0006950, 1901700,
0033554, 0009991). This analysis has also identified novel
cellular processes that are possibly altered in the intestine
of insulin-resistant subjects. GO terms concerning cell
death regulation were particularly frequent in the top list
of GO biological processes (GO: 0010941, 0042981,
0043067, 0042981, 0043068, 0043065). Finally, several GO
Table 1 Differentially expressed genes in the intestine of insulin-resistant compared to insulin-sensitive subjects
Function Genes Fold change
Intestinal peptides GIP Glucose inhibitory peptide −1.72
GKN1 Gastrokine 1 −1.54
GKN2 Gastrokine 2 −1.51
VIP Vasoactive intestinal polypeptide 1.30
Inflammation and oxidative stress PTGS2 Prostaglandin-endoperoxide synthase – COX-2 1.20
DUSD1 Dual specificity phosphatase 1 1.37
S100A8 S100 calcium binding protein A8 1.59
S100A9 S100 calcium binding protein A9 1.51
IL1B Interleukin 1 beta 1.21
GPX8 Glutathione peroxidase 8 1.21
FOS Cellular oncogene c-Fos 1.55
JUN Jun proto-oncogene 1.32
Transporters SLC28A2 Sodium-coupled nucleoside transporter −1.68
SLC2A3 Facilitated glucose transporter 3 1.25
Extracellular matrix MUC5AC Mucin 5 AC −1.58
MUC2 Mucin 2 −1.32
MUC6 Mucin 6 1.21
MMP7 Metalloproteinase 7 1.27
VIL1 Villin 1 −1.22
Digestive functions PGA5 Pepsinogen A −1.97
LCT Lactase 1.76
GLB1 β-galactosidase −1.21
PNLIPRP2 Pancreatic lipase 1.30
PRSS1 Trypsin 1 1.24
ELA3A Elastase 1.25
Immunity GP2 Glycoprotein 2 1.38
HLA-A Major histocompatibility complex class I A 2.63
HLA-C Major histocompatibility complex class I C −1.20
HLA-F Major histocompatibility complex class I F −1.28
HLA-DQA1 Major histocompatibility complex class II DQ alpha 1 1.38
HLA-DQB1 Major histocompatibility complex class II DQ beta 1 1.22
HLA-DRB1 Major histocompatibility complex class II DR beta 1 −1.35
HLA-DRB4 Major histocompatibility complex class II DR beta 4 1.39
Cholesterol homeostasis LDLR Low density lipoprotein receptor 1.30
APOD Apolipoprotein D-III 1.20
APOA1 Apolipoprotein A-I −1.37
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terms involved in cellular response to a broad-ranging
number of stimulus (GO: 0009991, 0050896, 0010035,
0008152, 0010033, 0009605, 0051716, 0009725, 0009719,
0031667) as well as in several general metabolic process
(GO: 0008152, 0044238, 0071704, 0044281, 0006629,
0008202) are significantly enriched in insulin-resistant sub-
jects, thereby providing an additional knowledge related to
the impact of insulin resistance on enterocyte metabolism.
Using more severe parameter analysis, three genes are
significantly and differently expressed in the intestine of
insulin-resistant subjects compared to insulin-sensitive
controls (fold change > 1.5 and FDR < 0.05). Insulinotropic
glucose-dependent peptide (GIP, 9.85 ± 0.36 vs. 9.06 ± 0.37)
and β-microseminoprotein (MSMB, 8.79 ± 1.16 vs. 7.54 ±
0.68) transcripts are significantly reduced in the intestine of
insulin-resistant subjects compared to the intestine of
insulin-sensitive controls. Inversely, expression levels of the
MTRNR2L1 gene, coding for the humanin like-1 protein,
are significantly higher (7.99 ± 0.39 vs. 8.58 ± 0.24) in the
intestine of insulin-resistant subjects than of insulin-
sensitive controls. Changes in expression levels of these 3
genes are successfully replicated using qPCR as shown in
the Fig. 2, right panel. qPCR fold changes of each target
gene significantly correlate with the expression values ob-
tained in the microarray experiments (Fig. 2, left panel).
This validation confirms that gene expression levels of GIP
and MSMB is reduced by 40 % (range 30–49 %) and 53 %
(range 32–67 %), respectively, but the MTRNR2L1 mRNA
levels are increased by 193 % (range 72–401 %) in the
intestine of insulin-resistant obese subjects compared to
the intestine of insulin-sensitive obese subjects.
Linear regression analysis is performed to explore the as-
sociation of anthropometric and biochemical parameters
with mRNA expression of aforementioned genes. As ex-
pected, HOMA-IR index is a significant correlate of GIP,
MSMB and MTRNR2L1 mRNA expression (r = ±0.50–
0.61, n = 18, p < 0.01). While GIP andMSMB mRNA levels
are not associated with BMI, MTRNR2L1 mRNA expres-
sion tends to be positively associated with this parameter
(r = 0.43, n = 18, p = 0.6). High fasting levels of TG, which
is a common component of insulin resistance, are signifi-
cantly associated with GIP (r = −0.43, n = 18, p = 0.05) and
MTRNR2L1 (r = 0.65, n = 18, p < 0.01) but only tend to be
associated with MSMB (r = −0.40, n = 18, p = 0.08). Sex
and age are not associated with the expression of these
genes. Our findings suggest that GIP and MSMB expres-
sion levels are reduced in the intestine in presence of insu-
lin resistance and dyslipidemia while increased MTRNR2L1
intestinal expression seems to be a function of alterations
in increased adiposity and the presence of glucose homeo-
stasis and lipid metabolism.
As intestinal insulin resistance seems to be triggered by
exacerbated oxidative stress and low-grade inflammation,
we have tested the impact of iron-ascorbate (Fe/Asc) oxy-
gen radical-generating system [16, 21] and lipopolysac-
charide (LPS)-mediated inflammation [16] on the mRNA
expression status of MSMB and MTRNR2L1 in Caco-2/15
cells. Since GIP has been found expressed only in
Table 2 Biological processes significantly enriched in differentially expressed genes in the intestine of insulin-resistant subjects
Regulators Role State (z-score) p Target genes regulated
PDGF Mitogenic ↗ (3.41) 10−16 ATF3, CNN1, CTGF, CYR61, DUSP1, EGR1, FOS, FOSB, GEM, IL1B, JUN, KLF6, RGS1,
SLC2A3, THBS1, ZFP36
Jnk Inflammation ↗ (2.77) 10−07 BIRC3, CTGF, DUSP1, IL1B, JUN, PTGS2, VCAM1, ZFP36
ERK Mitogenic ↗ (2.62) 10−09 CTGF, DUSP1, EGR1, FOS, HBEGF, JUN, MUC5AC, PDK4, PTGS2, THBS1, ZFP36
F7 Coagulation ↗ (2.40) 10−07 CTGF, EGR1, FOS, HBEGF, IL1B, ZFP36
TREM1 Inflammation ↗ (2.33) 10−05 ATF3, CFB, EGR1, GADD45B, GEM, HBEGF, IL1B, PTGS2, RGS1, THBS1
C/EBPα Transcription ↗ (2.22) 10−03 BTG2, CSF3R, CXCR4, PTGS2, S100A9
CD40LG Immunity ↗ (2.20) 10−05 BIRC3, E2F2, HLA-DQA1, HLA-DRB4, IL1B, PTGS2, VCAM1
MAP2K1/2 Mitogenic ↗ (2.19) 10−05 ATF3, CTGF, DUSP1, EGR1, IL1B
IL1α Inflammation ↗ (2.17) 10−03 BIRC3, IL1B, PTGS2, S100A9, SERPINA3
IFNγ Inflammation ↗ (2.16) 10−03 ATF3, CXCR4, HLA-A/C/DQB1, IL1B, KLF6, PTGS2, VCAM1
NUPR1 Transcription ↗ (2.12) 10−01 ATF3, BRI3BP, CXCR4, CYR61, HBEGF, KLF6, SIK1, ZFAND2
SELPLG Inflammation ↗ (2.00) 10−04 CLK1, CXCR4, FOS, IL1B
SMAD4 Transcription ↗ (2.00) 10−02 CTGF, GADD45B, IRAK3, THBS1
P38 MAPK Inflammation ↗ (2.00) 10−06 ATF3, CD55, CTGF, EGR1, FOS, IL1B, JUN, MUC5AC, PTGS2
TLR4 Inflammation ↗ (2.00) 10−05 ATF3, IL1B, IRAK3, MUC5AC, VCAM1
IgG Immunity ↘ (−2.24) 10−03 DUSP1, IL1B, LDLR, SLC2A3, ZFP36
Hdac Deacetylases ↘ (−2.57) 10−07 ATF3, EGR1, FOS, GADD45B, JUN, KLF6, KLF9
↗: Biological processes prediced to be increased
↘: Biological processes predicted to be decreased
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enteroendocrine K-cells, and mRNA levels of this gene
have not been assessed in enterocytes. On the other hand,
MSMB and MTRNR2L1 were previously demonstrated to
be expressed in various epithelial cells [22, 23]. Treatment
of Caco-2/15 cells with Fe/Asc do not significantly alter
MSMB mRNA levels while LPS administration induce it
(Fig. 3a, b). The addition of Fe/Asc and LPS to the cell cul-
ture medium significantly increases the mRNA expression
of MTRNR2L1 (Fig. 3c, d). Therefore, cellular MTRNR2L1
displays the same expression pattern observed in the intes-
tine of insulin-resistant subjects, which is not exactly the
case forMSMB.
Discussion
Insulin signaling defects can disturb metabolic functions
in liver, adipose tissue and muscle. They represent key
pharmacological targets to alleviate insulin resistance-
related risk factors or diseases [24]. Animal and human
Fig. 2 Differentially expressed genes in the intestine of insulin-resistant compared to insulin-sensitive subjects. Left panel illustrate spearman correlation
of gene expression levels obtained with microarray and mRNA expression measure by qPCR. Right panel illustrate mRNA expression measured by
qPCR of a GIP, b MSMB, and c MTRNR2L1 in the intestine of insulin-sensitive (IS) (n = 9) and insulin-resistant (IR) subjects (n = 9). * p < 0.05 (Wilcoxson
signed-rank test)
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studies have recently allowed to display a similar behav-
ior in the intestine of obese and insulin-resistant subjects
[3–10, 25, 26]. Since these defects were accompanied with
an intestinal TRL overproduction, we have argued that
postprandial dyslipidemia associated to insulin resistance
and T2D is at least partially driven by an adverse intestinal
lipid metabolism [11, 27]. In fact, we could test this hy-
pothesis in human intestine, which allowed us to show
that defects in insulin signalling homeostasis are related to
the presence of oxidative stress and chronic low-grade in-
flammation [10]. The aim of the present investigation is to
extend these findings by identifying additional intestinal
key factors implicated in these disorders using the power-
ful RNA microarray approach using the intestine of indi-
viduals with a relatively low or high systemic insulin
resistance state. We have detected 195 differentially
expressed genes and have found that 36 of them were
previously noted to be involved in specific intestinal
functions, including digestion, extracellular matrix, endo-
crine system, immunity, inflammation/oxidative stress and
cholesterol metabolism. Moreover, these differentially
expressed genes point to a potential activation of several
metabolic pathways associated with cell growth, immunity,
transcription regulation and especially inflammatory cell
signaling. Other cellular processes identified by GO ana-
lysis include cell death regulation, response to stimulus
(i.e., nutrients, hormones, inflammation) and metabolic
processes. Using more stringent analysis criteria (fold
change > 1.5 and FDR < 0.05), we have discovered 3 differ-
entially expressed genes in the intestine of insulin-resistant
compared to the intestine of insulin-sensitive obese sub-
jects. Intestinal transcripts of the GIP and MSMB are
down-regulated, but those of MTRNR2L1 show a signifi-
cant increase in insulin-resistant subjects. These observa-
tions suggest that while mRNA profile seems relatively
stable in the intestine of obese subjects, the expression of
few specific genes are altered in conditions of insulin re-
sistance. Interestingly, we observe that MTRNR2L1 mRNA
can be altered by either oxidative stress or inflammation in
Caco-2/15 cells. This study contributes to the identifica-
tion of potential key factors implicated in aberrant intes-
tinal adaptation leading to increased postprandial lipid and
Fig. 3 a-b MSMB, and c-d MTRNR2L1 mRNA expression levels in Caco-2/15 cells following exposure to oxidative stress and inflammatory conditions.
Caco-2/15 cells were cultured in the presence or absence of (a-c) Fe/Asc (200 μM/2 mM) for 6 h and of (b-d) LPS (150 μg/mL) for 24 h. Messenger
RNA expression was measured by qPCR (ΔΔCt). * p < 0.05 (Student’s t-test)
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lipoprotein synthesis in presence of systemic insulin resist-
ance. This condition is known to contribute to atherogenic
dyslipidemia characteristic to obese and T2D subjects.
As mentioned before, the transcript profiling indicated
that some genes are differentially expressed in the intestine
of insulin-resistant subjects compared to the intestine of
insulin-sensitive subjects. A large number of these genes
are known to play a key role in the intestine. Genes coding
for enzymes involved in food digestion are particularly well
represented on this list as well as in the top-ranked GO
terms. Although no particular tendency is observed in the
expression of these genes between the two groups of sub-
jects, they are involved in the hydrolysis of all nutrient
classes (i.e., carbohydrates, proteins and lipids). An altered
expression pattern is also observed in some extracellular
matrix-related genes, especially those coding for mucin
proteins. The latter create an insoluble mucous barrier
that serves to protect intestinal wall integrity and to coord-
inate the interactions between intestinal luminal content
and epithelial cells [28]. Increased mucin mass as well as
alterations in the expression profile of a number of mucin
members were previously reported in diabetic animal
models [29]. The association of Akkermansia muciniphila,
a mucin-degrading bacteria residing in the mucus layer, in
conditions of obesity and systemic insulin resistance, fur-
ther supports the hypothesis that the mucin-dependent
mucus layer plays a key role in intestinal dysregulation
[30]. In addition to the observed reduction of the GIP ex-
pression in presence of insulin resistance, three other in-
testinal peptides are differentially regulated. Gastrokine 1
and 2 are down-regulated in the intestine of insulin-
resistant subjects, an observation in line with previous
studies reporting decreased gastrokine expression in pro-
inflammatory environment [31]. On the other hand, the
increased levels of vasoactive intestinal polypeptide (VIP)
transcript in the intestine of insulin-resistant subjects cor-
roborates previous observation of higher VIP levels in
obese, dyslipidemic and insulin-resistant subjects [32].
The presence of elevated oxidative stress and low-grade
inflammation has been hypothesized to be intimately re-
lated to progression of insulin resistance and other
obesity-related disorders [33]. We have previously exam-
ined several oxidative stress and inflammatory markers in
the intestine of severely obese subjects with insulin resist-
ance [10]. Reduced antioxidant defence and higher levels
of lipid peroxidation by-product are observed in these sub-
jects. Moreover, increased activation of inflammatory path-
ways (i.e., p38 MAPK and NF-κB) in presence of insulin
resistance is evidenced together with elevated protein mass
of IL-6, ICAM and COX-2, as well as of the mRNA levels
of TNF-α, [10]. The present findings provide additional
evidence that systemic insulin resistance is associated with
the induction of several intestinal inflammatory pathways.
Indeed, eight differentially expressed genes related to
inflammation and oxidative stress are identified in the in-
testine of insulin-resistant subjects using the microarray
approach. Among them, it is worth mentioning COX-2
(the rate limiting enzyme of prostaglandin biogenesis) that
showed higher mRNA expression levels in the intestine of
insulin-resistant subjects. This observation is coherent
with our previous observations related to increased COX-
2 protein levels in these subjects [10]. Several top-ranked
significantly enriched GO terms are related to stress re-
sponse and inflammation. More specifically, analysis of the
present data have identified several inflammatory pathways
enriched in differentially expressed genes, including Jnk,
TREM1, IL1α, IFNγ, SELPLG, p38-MAPK and TLR4.
Interestingly, p38-MAPK pathway activation in presence
of systemic insulin-resistance has also been previously
confirmed by our group in the intestine of these subjects,
as monitored by the phosphorylation state of the p38
MAPK kinase [10]. Using the two approaches, i.e., GO en-
richment analysis and IPA, we have found that insulin-
resistance state is also associated with gene profiling re-
modeling related to immunity [i.e., several members of the
class I and II major histocompatibility complex (MHC)].
Alterations in the expression of these genes have been pre-
viously demonstrated in the adipocytes of obese subjects
[34]. Moreover, mice deficient in class II MHC develop
less inflammation in the adipose tissue and remained insu-
lin sensitive when fed with a high-fat diet, an effect appar-
ently mediated by macrophage and T-cell activation [34].
Apparently, changes in the expression profile of MHC
genes may be associated with the exacerbated inflamma-
tory state and decreased insulin response in the small in-
testine of insulin-resistant subjects, but additional work is
necessary to determine the mechanisms. Collectively, these
data support the hypothesis that oxidative stress and
chronic low-grade inflammation are exacerbated in the in-
testine of insulin-resistant subjects, which may contribute
to reducing local insulin sensitivity while promoting intes-
tinal dysregulation leading to postprandial dyslipidemia.
Finally, the GO enrichment analysis has deepened the ana-
lysis of the data through the identification of three novel
families linked to cellular processes and modulated by the
presence of systemic insulin resistance. The presence of
several GO terms concerning cell death regulation in the
top-ranked GO processes suggest that an abnormal regula-
tion of the small intestine epithelium renewal may be in-
volved in this condition. GO terms related to the cellular
response to a broad-ranging number of stimulus as well as
in several general metabolic processes are also significantly
enriched in insulin-resistant subjects. These latter GO
terms suggest that insulin-resistance profoundly alter en-
terocyte metabolic response to stimulus from it immediate
environment, which supports the hypothesis of dysfunc-
tional enterocytes leading to postprandial dyslipidemia in
insulin-resistant subjects.
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A robust and interesting finding of this study is the
identification of three differentially expressed genes in
the intestine of insulin-resistant obese subjects. Messen-
ger RNA changes of GIP, MSMB and MTRNR2L1 genes
have been validated by qPCR in the same intestinal sam-
ples. GIP, one of the two major incretin hormones with
the glucagon-like peptide (GLP1), is secreted by enter-
oendocrine K-cells in the proximal small intestine in re-
sponse to glucose hyperosmolality. This gut hormone
amplifies pancreatic insulin secretion and stimulates
proliferation of pancreatic β-cells. Besides the pancreas,
the GIP receptor is also expressed in adipose tissue,
brain and stomach as well as in the proximal portion of
the small intestine [35]. In this context, GIP was found
to stimulate dipeptide and glucose absorption in entero-
cytes, and to moderately inhibit gastric acid secretion
and gastric emptying [36]. Interestingly, the decreased
GIP expression levels noted in the present work is co-
herent with previous studies on insulin resistance and
T2D [35], reporting reduced β-cell responsiveness to
GIP [37] and lower postprandial GIP circulating levels in
diabetes [38]. We may therefore deduce that GIP mRNA
reduction in the intestine exposed to systemic insulin re-
sistance corroborates GIP signaling defects in insulin-
resistant and T2D subjects. Down-regulation of GIP ex-
pression may suggest reduced mRNA expression levels
or may alternatively indicate a decrease in the number
of K-cells in the duodenum in presence of systemic insu-
lin resistance. While the precise GIP functions, espe-
cially in non-pancreatic tissue, remained to be explored,
the decreased GIP expression in the intestine has the
potential to influence overall energy metabolism through
the regulation of insulin secretion.
Messenger RNA of the MTRNR2L1 gene, coding for
humanin-like 1 protein, is increased in the intestine of
insulin-resistant subjects compared to the intestine of
insulin-sensitive subjects. This gene is one of the numerous
nuclear copies of the mitochondrial MTRNR2 gene coding
for the humanin protein [22]. While little is known on
these nuclear copies, some authors have reported that
mitochondrial humanin is linked to insulin resistance [39].
We have noticed that the expression of the two genes,
MTRNR2L1 and MTRNR2, is upregulated in the intestine
of subjects with insulin resistance (Fig. 2c and data not
shown), which supports the possibility that both genes
maintain a similar expression pattern during evolution
[22]. This gene family codes for highly similar small
secretory 21 to 24- amino acid peptides [22]. While they
were initially identified as survival factors in the context of
Alzheimer disease [40], they also seem to protect cells from
oxidative stress, starvation and hypoxia [41]. Increased
humanin protein mass was noted in atherosclerotic plaques
of symptomatic subjects and in epithelial cells of ApoE-de-
ficient mice on high-cholesterol diet to possibly protect
cells against apoptosis [42]. Accordingly, we could success-
fully demonstrate that pro-oxidant (i.e., Fe/Asc) and pro-
inflammatory (i.e., LPS) stimuli induce MTRNR2L1 mRNA
expression in Caco-2/15 cells. Potential humanin-like 1 role
in cell may therefore represent an attempt to alleviate ad-
verse effects of oxidative stress on enterocytes. However,
further studies are needed to define the precise regulation
and function of humanin and humanin-like proteins in this
tissue.
We also observe a decreased expression of the β-
microseminoprotein, a member of the immunoglobulin
binding factor family. This protein is expressed in several
epithelial cells and has been shown to inhibit cancer cell
growth and to possess antifungal activity [23]. There is
presently no available information reporting a potential link
between metabolic diseases and the β-microseminoprotein.
Moreover, a significant role in small intestine cancer preva-
lence is improbable as it remains a very uncommon cancer
even in obese subjects [43].
This study represents a unique opportunity to assess
the impact of systemic insulin resistance on intestinal
metabolism, but we acknowledge some limitations. Due
to the technical difficulty inherent to intestinal sampling,
only subjects with obesity were included in his study
and some observations could be specific to this popula-
tion. The cross-sectional design prevents us to infer
about a cause-effect relationship between intestinal gene
expression and intestinal metabolic dysregulation or dys-
lipidemia in these subjects. Specific experiments and
longitudinal studies should be performed to definitively
conclude on the involvement of these genes in the estab-
lishment of intestinal insulin resistance and postprandial
lipid metabolism alterations.
Conclusion
We have demonstrated that human small intestine tran-
scriptome show evidences of functional adaptations when
exposed to systemic insulin resistance. Genes involved in
digestion, extracellular matrix, intestinal peptides and
cholesterol metabolism were differentially regulated in the
intestine of insulin-resistant subjects compared to the in-
testine of insulin-sensitive subjects. Nevertheless, insulin
resistance was particularly associated with an amplifi-
cation of oxidative stress and chronic low-grade inflam-
mation which should now be considered as potential
contributors to the development of an altered intestinal
lipid metabolism in an unfavorable environment. Some
genes and pathways identified are likely to contribute to
the development of a dysfunctional enteric state leading to
lipid and lipoprotein metabolic alterations and to the post-
prandial dyslipidemia commonly observed in patients with
insulin resistance and T2D. Additional studies are needed
to define whether these changes are related to the
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progression of intestinal metabolism dysregulation or rep-
resent an adaptive response to this state.
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